Literature DB >> 32831904

Correction to: Very long chain fatty acids are an important marker of nutritional status in patients with anorexia nervosa: a case control study.

Miki Shimizu1, Keisuke Kawai1,2, Makoto Yamashita1, Masayasu Shoji2, Shu Takakura1, Tomokazu Hata1, Megumi Nakashima1, Keita Tatsushima1,2, Kazunari Tanaka3, Nobuyuki Sudo1.   

Abstract

[This corrects the article DOI: 10.1186/s13030-020-00186-8.].
© The Author(s) 2020.

Entities:  

Year:  2020        PMID: 32831904      PMCID: PMC7422507          DOI: 10.1186/s13030-020-00192-w

Source DB:  PubMed          Journal:  Biopsychosoc Med        ISSN: 1751-0759


Correction to: Biopsychosoc Med (2020) 14:14 https://doi.org/10.1186/s13030-020-00186-8 Following publication of the original article [1], the authors identified an error in Table 1, Table 2 and Table 3. The dagger mark (♱) in the Tables 1, 2, 3 disappears in the pdf version due to typesetting error. The HTML version is correct.
Table 1

Demographic data at admission and after 3 months of treatment

AN-R (n = 38)AN-BP (n = 31)Control group
on admissionafter 3 monthson admissionafter 3 months(n = 25)
Age (years)28.42 ± 12.3928.42 ± 12.3932.43 ± 8.1932.30 ± 8.1929.33 ± 6.55
Duration of anorexia (days)2114.08 ± 3255.41NR2629.29 ± 2037.48NRNR
Height (cm)154.44 ± 5.39∗154.77 ± 5.85∗158.27 ± 3.59158.47 ± 3.71160.16 ± 3.02
Body weight (kg)30.73 ± 5.50∗37.86 ± 6.04∗†30.33 ± 3.76∗38.12 ± 5.03∗†51.99 ± 4.79
Body mass index (kg/m2)12.81 ± 2.00∗15.77 ± 2.15∗†12.17 ± 1.58∗15.25 ± 2.00∗†20.20 ± 1.91
Fat mass (g)3498.3 ± 1611.318272.79 ± 3604.42†4054.34 ± 1572.679557.05 ± 5310.85†NR
Lean body mass (g)27,283.02 ± 3242.1830,321.15 ± 3556.30†26,914.63 ± 2493.526,616.08 ± 2334.50†NR
Percentage of fat mass (%)10.62 ± 3.8120.04 ± 7.09†12.07 ± 3.7020.42 ± 3.77†NR

1AN-R Anorexia Nervosa Restricting type, AN-BP Anorexia Nervosa Binge-Eating/Purging type

2NR: denotes data not reported. Values presented as the mean ± SD for the number of observations indicated

3Significant differences in the comparisons of AN-R and AN-BP with controls: ∗P < 0.05

4Significant differences between values on admission and after 3 months: †P < 0.05

Table 2

Biochemical parameters on admission and after 3 months of treatment

AN-R (n = 38)AN-BP (n = 31)Control group
on admissionafter 3 monthson admissionafter 3 months(n = 25)
Glucose (mg/l)79.79 ± 16.9380.32 ± 7.7376.7 ± 12.09∗81.42 ± 7.42†85.40 ± 8.95
Total cholesterol (mg/dl)189.32 ± 60.08193 ± 37.17228.83 ± 50.95∗208.68 ± 42.71200.16 ± 28.46
Triacylglycerol (mg/dl)74.24 ± 37.2873.55 ± 23.06108.73 ± 47.99∗83.26 ± 44.5158.54 ± 19.45
HDL-C (mg/dl)70.47 ± 19.6369.91 ± 17.4674.2 ± 25.3270.79 ± 15.6674.24 ± 16.42
TSH (μU/ml)2.61 ± 2.272.31 ± 1.291.629 ± 1.161.79 ± 0.652.01 ± 0.72
FT3 (pg/ml)1.93 ± 0.60∗2.71 ± 0.69∗†2.06 ± 0.53∗2.35 ± 0.32∗†3.21 ± 0.40
FT4 (ng/dl)1.07 ± 0.24∗0.92 ± 0.18∗†1.16 ± 0.330.92 ± 0.18∗†1.29 ± 0.20
Cortisol (μg/dl)20.19 ± 6.56∗12.79 ± 4.11†20.33 ± 6.47∗13.26 ± 4.09†15.68 ± 3.70
GH (nU/ml)12.30 ± 19.84∗3.01 ± 6.78†8.65 ± 14.002.52 ± 1.94†2.50 ± 2.67
AST (IU/l)43.82 ± 48.3234.81 ± 23.3072.48 ± 203.6334.83 ± 27.36NR
ALT (IU/l)50.34 ± 40.2647.36 ± 39.6753.00 ± 99.2942.17 ± 26.80NR

1AN-R Anorexia Nervosa Restricting type, AN-BP Anorexia Nervosa Binge-Eating/Purging type

2FT3: free triiodothyronine, FT4: free thyroxine, GH: growth hormone

3Values presented as the mean ± SD for the number of observations indicated

4Significant differences in the comparisons of the AN-R and AN-BP groups with controls: ∗P < 0.05

5Significant differences between values on admission and after 3 months: †P < 0.05

6NR: denotes data not reported. The normal ranges for AST and ALT are 7–38 IU/L and 4–44 IU/L, respectively, based on the reference range used by our laboratory

Table 3

Fatty acid composition on admission and after 3 months of treatment

AN-R (n=38)AN-BP (n=31)Control group
on admissionafter 3 monthson admissionafter 3 months(n = 25)
C12:0 (μg/ml)2.62 ± 1.983.10 ± 1.413.82 ± 3.173.84 ± 3.193.66 ± 4.16
C14:0 (μg/ml)16.12 ± 5.5925.58 ± 7.04∗†21.78 ± 8.85∗29.89 ± 13.75∗15.48 ± 6.20
C14:1n-5 (μg/ml)1.42 ± 0.712.15 ± 0.87∗†2.27 ± 1.27∗3.01 ± 1.58∗1.29 ± 0.65
C16:0 (μg/ml)488.11 ± 162.94493.89 ± 93.78603.93 ± 156.37∗537.83 ± 130.01457.96 ± 70.72
C16:1n-7 (μg/ml)42.55 ± 23.3546.47 ± 19.0983.35 ± 44.26∗55.39 ± 35.42†35.64 ± 11.76
C18:0 (μg/ml)231.11 ± 49.62243.47 ± 39.59274.06 ± 63.23∗263.44 ± 41.13232.80 ± 39.22
C18:1n-9 (μg/ml)523.11 ± 253.63406.00 ± 68.07721.10 ± 209.79∗458.22 ± 126.84†461.12 ± 100.02
C18:2n-6 (μg/ml)794.34 ± 217.25736.31 ± 170.57973.61 ± 286.45∗851.22 ± 173.29820.48 ± 160.14
C18:3n-6 (μg/ml)5.71 ± 4.908.71 ± 5.448.40 ± 5.679.94 ± 5.17∗6.11 ± 3.32
C18:3n-3 (μg/ml)20.48 ± 8.39∗22.95 ± 7.01∗24.86 ± 8.53∗25.78 ± 10.44∗15.72 ± 5.57
C20:0 (μg/ml)2.04 ± 0.57∗1.83 ± 0.412.15 ± 0.66∗1.82 ± 0.391.56 ± 0.29
C20:1n-9 (μg/ml)6.07 ± 2.40∗5.54 ± 2.645.89 ± 2.19∗6.57 ± 3.5∗4.26 ± 0.86
C20:2n-6 (μg/ml)5.71 ± 3.255.83 ± 1.39∗6.87 ± 3.78∗7.26 ± 2.01∗4.69 ± 1.26
C20:3n-9 (μg/ml)1.29 ± 1.451.15 ± 0.301.50 ± 0.681.54 ± 0.861.36 ± 0.37
C20:3n-6 (μg/ml)21.36 ± 10.6529.78 ± 10.06†29.06 ± 17.4737.00 ± 16.44∗†24.06 ± 8.59
C20:4n-6 (μg/ml)163.21 ± 62.70132.47 ± 40.96∗175.06 ± 61.08151.33 ± 42.28183.84 ± 47.08
C20:5n-3 (μg/ml)60.09 ± 44.89∗86.89 ± 30.13∗†40.98 ± 28.9775.94 ± 30.24∗†36.08 ± 22.78
C22:0 (μg/ml)1.54 ± 0.77∗1.66 ± 1.06∗1.46 ± 0.86∗1.75 ± 0.97∗0.90 ± 0.42
C22:1n-9 (μg/ml)2.63 ± 0.98∗2.62 ± 2.202.72 ± 1.21∗2.99 ± 2.231.76 ± 0.65
C22:5n-3 (μg/ml)17.82 ± 6.6025.37 ± 6.26∗†19.06 ± 5.95∗25.44 ± 8.23∗†15.73 ± 3.24
C22:6n-3 (μg/ml)98.26 ± 44.55114.63 ± 44.99†96.71 ± 41.14100.11 ± 38.0784.92 ± 27.89
C24:0 (μg/ml)1.46 ± 0.56∗1.42 ± 0.57∗1.62 ± 0.65∗1.58 ± 8.25∗0.96 ± 0.28
C24:1n-9 (μg/ml)2.41 ± 1.581.90 ± 1.322.42 ± 1.592.33 ± 8.261.60 ± 0.47
C22:4n-6 (μg/ml)3.86 ± 2.073.42 ± 1.194.71 ± 1.71∗4.33 ± 2.073.72 ± 0.92
Total (μg/ml)2515.84 ± 703.482401.55 ± 347.343096.36 ± 716.48∗2658.56 ± 8.272417.48 ± 363.46

1AN-R Anorexia Nervosa Restricting type, AN-BP Anorexia Nervosa Binge-Eating/Purging type

2Values presented as the mean ± SD for the number of observations indicated

3Significant differences in the comparisons of the AN-R and AN-BP groups with controls: ∗P < 0.05

4Significant differences between values on admission and after 3 months: †P < 0.05

Demographic data at admission and after 3 months of treatment 1AN-R Anorexia Nervosa Restricting type, AN-BP Anorexia Nervosa Binge-Eating/Purging type 2NR: denotes data not reported. Values presented as the mean ± SD for the number of observations indicated 3Significant differences in the comparisons of AN-R and AN-BP with controls: ∗P < 0.05 4Significant differences between values on admission and after 3 months: †P < 0.05 Biochemical parameters on admission and after 3 months of treatment 1AN-R Anorexia Nervosa Restricting type, AN-BP Anorexia Nervosa Binge-Eating/Purging type 2FT3: free triiodothyronine, FT4: free thyroxine, GH: growth hormone 3Values presented as the mean ± SD for the number of observations indicated 4Significant differences in the comparisons of the AN-R and AN-BP groups with controls: ∗P < 0.05 5Significant differences between values on admission and after 3 months: †P < 0.05 6NR: denotes data not reported. The normal ranges for AST and ALT are 7–38 IU/L and 4–44 IU/L, respectively, based on the reference range used by our laboratory Fatty acid composition on admission and after 3 months of treatment 1AN-R Anorexia Nervosa Restricting type, AN-BP Anorexia Nervosa Binge-Eating/Purging type 2Values presented as the mean ± SD for the number of observations indicated 3Significant differences in the comparisons of the AN-R and AN-BP groups with controls: ∗P < 0.05 4Significant differences between values on admission and after 3 months: †P < 0.05 The correct tables have been included in this correction, and the original article has been corrected.
  1 in total

1.  Very long chain fatty acids are an important marker of nutritional status in patients with anorexia nervosa: a case control study.

Authors:  Miki Shimizu; Keisuke Kawai; Makoto Yamashita; Masayasu Shoji; Shu Takakura; Tomokazu Hata; Megumi Nakashima; Keita Tatsushima; Kazunari Tanaka; Nobuyuki Sudo
Journal:  Biopsychosoc Med       Date:  2020-07-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.